Concise Review: Mesenchymal Stromal Cell-Based Approaches for the Treatment of Acute Respiratory Distress and Sepsis Syndromes

CHRISTIAN L. JOHNSON, YORICK SOEDER, MARC H. DAHLKE

Key Words. Mesenchymal stromal cells • Sepsis syndrome • Acute respiratory distress syndrome • Immunomodulation • Cell therapy

ABSTRACT

Despite extensive research on candidate pharmacological treatments and a significant and increasing prevalence, sepsis syndrome, and acute respiratory distress syndrome (ARDS) remain areas of unmet clinical need. Preclinical studies examining mesenchymal stromal cell (MSCs) based-therapies have provided compelling evidence of potential benefit; however, the precise mechanism by which MSCs exert a therapeutic influence, and whether MSC application is efficacious in humans, remains unknown. Detailed evaluation of the limited number of human trials so far completed is further hampered as a result of variations in trial design and biomarker selection. This review provides a concise summary of current preclinical and clinical knowledge of MSCs as a cell therapy for sepsis syndrome and ARDS. The challenges of modeling such heterogeneous and rapidly progressive disease states are considered and we discuss how lessons from previous studies of pharmacological treatments for sepsis syndrome and ARDS might be used to inform and refine the design of the next generation of MSC clinical trials.

STEM CELLS TRANSLATIONAL MEDICINE

2017;6:1141–1151

SIGNIFICANCE STATEMENT

Mesenchymal stromal cells (MSCs) are increasingly being assessed as therapeutic for a range of immunological diseases. The present report provides an analysis of the current preclinical and clinical knowledge of MSCs as a potential cell-based treatment for sepsis syndrome and acute respiratory distress syndrome.

INTRODUCTION

Sepsis is a potentially lethal syndrome that can develop following an infection in which a breakdown in immune homeostasis results in both pro-inflammatory and anti-inflammatory mechanisms becoming uncoupled from normal regulation [1]. Despite decades of research, sepsis syndrome remains a global health concern with no causal treatment. Current estimates indicate that there are in excess of 19 million new cases worldwide per year [2]. While the prevalence of severe sepsis (sepsis accompanied by acute organ dysfunction) on ICU’s of western countries is comparable (USA 11.8% [3], Germany 11.0% [4], Italy 11.6% [5]), it is likely disproportionally higher in low- and middle-income countries [6]. Sepsis syndrome ranks as the leading cause of death in hospitalized patients [7] with mortality rates ranging from between 20 and 50% [4, 8]. Sepsis is inherently heterogeneous and its treatment represents a significant challenge. Clinical outcomes are influenced by individual patient factors, including age, gender and race [8] and by both the infection agent and the site of clinical manifestation. Currently there is no gold-standard diagnostic test to predict severity and to guide patient treatment [9]. Although sepsis syndrome is normally considered to be the clinical response to a suspected or proven infection [10], it can also occur following sterile tissue injury [7]. Despite a recent proposal [9] to revise the previous consensus definition of sepsis and septic shock [11] that recommended removal of the term “severe sepsis” and replacement of SIRS criteria in sepsis diagnosis with the “Sequential Organ Failure Assessment” (SOFA) and quick SOFA (qSOFA) (Table 1) score systems, concerns have been raised that there remains a disproportionate emphasis on infection [12, 13].

PATHOGENESIS

In sepsis syndrome, an inappropriate immune response can persist after resolution of the initial causal infection. This is primarily driven by the
in the serum [7]. Notably, the primary host responses to infection appear similar to that of sterile inflammation and ischemic reperfusion injury [18], providing a possible explanation for sepsis of a noninfectious origin or mixed forms of sepsis syndrome. Sepsis can promote the onset of a variety of organ specific complications including acute kidney injury (AKI), acute liver injury, myocardial dysfunction, acute lung injury (ALI), and acute respiratory distress syndrome (ARDS). The study of ALI and ARDS, in which unregulated inflammation focused in the lungs leads to a breakdown of the pulmonary capillary endothelial barriers and results in fluid accumulation, will be considered in further detail within this review.

### CURRENT TREATMENT REGIMENS

Treatment of sepsis syndrome places a significant burden on healthcare infrastructure. In the USA alone, annual primary treatment costs in 2007 were estimated at $24.3 billion [19]. Current evidence-based treatment recommendations are published by the Surviving Sepsis Campaign [20] and consist primarily of a resuscitation bundle (to be completed within 6 hours) and a management bundle (to be completed within 24 hours). The resuscitation bundle is composed of; (a) a rapid source control and administration of empirical broad spectrum antibiotics and if necessary vasopressors and fluid resuscitation, (b) an early goal-directed therapy (EGDT) to achieve target values for central venous pressure, mean arterial pressure, urine output, both central venous and arterial
oxygen saturation, hematocrit, cardiac index, and systemic oxygen consumption. The continued application of current treatment guidelines has led to improved algorithms for treating septic patients; however alone these may be insufficient to produce further decreases in sepsis mortality rates. For example, while antibiotic treatment is a key pharmacological intervention in sepsis management, the rising incidence of antibiotic resistant microbes is recognized as an emerging obstacle [10]. Furthermore, a recent meta-analysis [21] on the impact of EGDT has called into question the benefits of this therapeutic approach. The authors reported that EGDT was not superior to standard of care for septic shock patients but was associated with both an increased admission to ICU and an increased utilization of ICU resources. Despite clinical trials examining potentially causal therapeutic compounds for sepsis treatment, including an IL-1 receptor antagonist [22], TNF-\(\alpha\) antagonist [23], human recombinant activated protein C (APC) [24], intravenous immunoglobulin G therapy [25], TLR4 antagonist [26], and talactoferrin [27], no new pharmacological therapies have entered the clinical routine [28].

**PRECLINICAL SEPSIS MODELS**

Small animal models have been used extensively to investigate the physiological process that lead to sepsis syndrome and ALI/ARDS, and to study the effects of potential therapeutics. Generally, these models introduce a systemic or a localized challenge into the host in order to induce a sepsis-like pathology [29]. In systemic challenge models, bacteria (i.e., *Escherichia coli* or bacterial-derived toxins (i.e., lipopolysaccharide, LPS) are administered into the animal by intravenous or intraperitoneal injection. The resulting rapid systemic release of pro-inflammatory cytokines, such as TNF-\(\alpha\) and IL-1, and an increase in hypodynamic cardiovascular activity, leads to onset of a septic shock-like state. In localized challenge models, a source of infection is introduced into a specific anatomical region. As the lung and abdominal cavity are the most commonly observed locations of infection in septic patients [30], models of pneumonia and peritonitis are frequently used. Endotoxicemia models utilizing LPS have been used extensively as they offer a convenient, reproducible method of experimentally inducing sepsis. However, the severity of LPS-induced sepsis can depend on the model species or strain being used. For example, a much higher equivalent LPS dose is required to induce a sepsis-like condition in mice than in human [31]; therefore, such models are unlikely to accurately reflect the human disease course. The cecal ligation and puncture (CLP) model is chiefly used in the study of abdominal sepsis as it is thought to closely mimic the clinical situation [32], comprising of both a tissue trauma and a mixed microbial infection. In CLP, the cecum is ligated distal to the ileocecal valve; puncturing of the ligated cecum then permits contamination of the peritoneal cavity with colonic-derived bacteria leading to the onset of an abdominal sepsis-like condition. An added advantage of CLP is that it is highly adaptable, both sepsis onset and severity can be manipulated by varying the frequency of cecum punctures, needle size and the length of the cecum ligated [29].

**MESenchymAL STROMAL CELLS**

Mesenchymal stromal cell (MSC) are non-hematopoietic, multipotent stromal precursor cells that can be isolated from tissues such as bone marrow, adipose, dental pulp, placenta, cord blood, and matrix [33]. MSC are capable of modulating the immune response [34] by both cell-to-cell contact and through the release of soluble paracrine factors including nitric oxide, indoleamine 2,3-dioxygenase, PGE\(_2\), TGF-\(\beta\), and IL-10 [35], [36]. MSC also promote expansion of the regulatory T cell (Treg) compartment [37]. In a model of solid organ transplantation, we [38] have identified that infusions of MSC and multipotent adult progenitor cell (MAPCs), a bone marrow derived cell that shares a number of MSC characteristics including multipotency and immunosuppressive potential, lead to an induction of myeloid-derived suppressor cells (MDSCs) to initially promote induction of pro-inflammatory Th17 followed by conversion into CD4\(^+\) Tregs. The last decade has witnessed a surge in the number of preclinical and early phase clinical trials studying multipotent cell-based technologies for indications including, but not limited to, GVHD, ischemic stroke, Crohn’s disease, motor neuron disease, and acute myocardial infarction. MSC possess a number of characteristics that make them an attractive therapeutic candidate; they can undergo extended expansion without detriment to their multipotency or self-renewal properties [39] and they exhibit low immunogenicity [40] and low tumorigenicity [41]. Our own mouse models have provided evidence that intravenously infused MSC are short-lived, with the lungs acting as the principle site of early enrapment [42]. This may be a benefit in those indications in which the lung is the principle region of tissue injury, such as in the case of ALI/ARDS, as this would facilitate a high local concentration of MSC directly at the site of inflammation. Furthermore, a rodent model of ALI has provided initial evidence that the route of cellular application (intravenous and intratracheal) can partially influence MSC activity [43]. However, it also might be counterproductive to apply MSC to patients where the pulmonary circuit is partially compromised as the potential for pulmonary embolism might be greater. MSCs are generally considered amendable to cryogenic storage [44]. Notwithstanding, there is evidence that senescence is enriched in MSC populations that have been subjected to freeze-thawing protocols [45] which may subsequently impair their immunosuppressive potency [46]. To date, the majority of pilot and early phase clinical studies have focused on autologous or syngeneic MSCs. However, the process of isolating, cultivating, and assessing patient-specific MSCs typically requires weeks, therefore prohibiting their use in those diseases with restrictive treatment windows. Consequently, studies are beginning to focus on allogeneic MSC as these cells would permit on-demand patient treatment. Currently, our own group is conducting a phase I clinical trial to assess the safety and feasibility of third-party MAPCs in liver transplant recipients [47]. Recently, positive results have been reported in a phase II randomized, double blind, multicenter trial designed to assess the safety and efficacy of a proprietary allogenic adipose-derived MSC (ADSC) to treat complex perianal fistulas in Crohn’s disease (ClinicalTrials.gov NCT01541579). Here, the authors reported that a significantly greater proportion of ADSC treated patients achieved the primary endpoint of combined remission at week 24 compared to the placebo group [48]. Certainly, the use of third-party “off-the-shelf” MSC-based would potentially enable an early therapeutic intervention such as is currently recommended in the treatment of sepsis syndrome.

**MSCs REDUCE INFLAMMATION**

In vivo models of sepsis and ALI/ARDS have shown MSCs treatment to improve survival and to positively influence a number of
### Table 2. Preclinical studies of mesenchymal stromal cells in treating ALI and sepsis in which mortality was assessed

| Model | Treatment | Dose regimen | Result of cell treatment | Author, Year [Ref.] |
|-------|-----------|--------------|--------------------------|---------------------|
| **Mouse, ALI, E. coli-induced** | Mouse BMSC (syngeneic) Mouse BMSC apoptotic (syngeneic) | $7.5 \times 10^5$ IT 4 hours post E. coli challenge | survival, IL-10, No change = TNF-α | Gupta et al. 2007 [49] |
| **Mouse, sepsis/colicitis, CLP** | Human ADSC Mouse ADSC (allo/syngeneic) | $1 \times 10^6$ IP 4 hours post CLP | survival, IL-10, bacterial clearance | Gonzalez-Rey et al. 2009 [50] |
| **Mouse, sepsis/colicitis, LPS** | Human ADSC | $3 \times 10^5$ or $1 \times 10^5$ IP 0.5 hours post LPS | TNF-α, IL-6, IL-1β, MIP-2. RANTES, IL-12, IFN-γ | | |
| **Mouse, sepsis, CLP** | Mouse BMSC (auto/allo) | $1 \times 10^6$ IV 24 hours prior or 1 hour post CLP | survival, kidney function, IL-10 | Nemeth et al. 2009 [51] |
| **Mouse, sepsis, CLP** | Mouse BMSC (allo) $+/−$ IL-10 overexpression | $1 \times 10^6$ IV 1 hour post CLP | IL-1β, TNF-α, IL-6, IL-10, TGF-β, VEGF, IL-12, IFN-γ | Bi et al. 2010 [52] |
| **Rat, ALI, bleomycin inhalation** | Rat BMSC (allo) $+/−$ antibodies | $1 \times 10^5$ IV 96 hours post bleomycin | survival, IL-6, IL-10, KC, JE, CCL5 | Lee et al. 2010 [53] |
| **Mouse, sepsis/ALI, CLP** | Mouse BMSC (allo) $+/−$ antibiotics | $2.5 \times 10^5$ IV 6 hours post CLP | survival, bacterial clearance, organ function | Mei et al. 2010 [54] |
| **Mouse, E. coli-induced** | Human UC-MSC | $1 \times 10^5$ IT 3 hours post E. coli challenge | survival, bacterial clearance | Kim et al. 2011 [55] |
| **Rat, ALI, LPS** | Rat BMSC (allo) | $1 \times 10^6$ IV 2 hours post LPS | survival (not significant), IL-10 | Liang et al. 2011 [56] |
| **Mouse, ALI, LPS** | Human UC-MSC | $1 \times 10^6$ IV 4 hours post LPS | IL-10, TNF-α, TNF-β, MPO survival | Sun et al. 2011 [57] |
| **Rat, sepsis, CLP** | Rat ADSC (auto) Rat BMSC apoptotic (auto) | $1.2 \times 10^5$ IV at 0.5, 6, & 18 hours post-CLP | Tregs (healthy only) | Chang et al. 2012 [58] |
| **Mouse, E. coli-induced** | Mouse BMSC (allo) | $7.5 \times 10^5$ IT 4 hours post E. coli challenge | survival, bacterial clearance | Gupta et al. 2012 [59] |
| **Mouse, sepsis, P. aeruginosa induced** | Human BMSC | $1 \times 10^6$ IV 1 hour post P. aeruginosa challenge | survival, bacterial clearance | Krasnodembskaya et al. 2012 [60] |
| **Rat, ALI, LPS** | Human UC-MSC | $5 \times 10^6$ IV 1 hour post LPS | IL-10, TNF-α, IL-6, MPO survival | Li et al. 2012 [61] |
| **Rat, VILI** | Rat BMSC (allo/conditioned medium) | $4 \times 10^6$ IV/IT 2.5–3 hours post VILI initiation | lung recovery | Curley et al. 2013 [62] |
| **Rat, ALI, Paraquat** | Rat BMSC (allo) $+/−$ methylprednisolone | $1 \times 10^6$ IV 6 hours post paraquat | survival, IL-10, SOD NF-xβ p65, TNF-α, IL-1β, IL-6, MDA survival | Yang et al. 2013 [63] |
| **Rat, ALI, LPS + chest impact** | Rat BMSC (syngeneic) | $2.5 \times 10^6$ IV 2 hours post LPS | TNF-α, IL-6, IL-10 survival | Zhao et al. 2013 [64] |
| **Mouse, sepsis, LPS** | Human BMSC alive/senescent | $1 \times 10^5$ IV 0.5 hour post LPS | TNF-α, IL-6 survival | Sepulveda et al. 2014 [46] |
| **Rat, sepsis-induced kidney injury, CLP** | Rat ADSC apoptotic (auto) $+/−$ melatonin | $1.2 \times 10^6$ IV at 0.5, 6, & 18 hours post-CLP | survival, kidney function | Chen et al. 2014 [65] |
An increase relative to baseline value; #, a decrease relative to baseline value.

manipulation, U. cecal bacteria challenge, CLP.

Table 2. Continued

| Model | Treatment | Dose regimen | Result of cell treatment | Author, Year [Ref.] |
|-------|-----------|--------------|--------------------------|---------------------|
| Rat, sepsis, CLP | Human BMSC | $5 \times 10^7$ IV 4 hours post E. coli challenge | Survival, IL-10, IL-12, IFN-γ | Devaney et al. 2015 [43] |
| Mouse, sepsis, E. coli induced | Mouse ADSC (auto) | $10^6$ RO at time of E. coli challenge | Survival, IL-10, TNF-α, IL-6 | Pedrazza et al. 2014 [67] |
| Mouse, sepsis, CLP | Human MenSC +/− antibiotics | $7.5 \times 10^6$ IP 3 hours post CLP | Survival, bacterial clearance, liver function | Alcayage-Miranda et al. 2015 [68] |
| Mouse, sepsis/ALI, CLP | Human BMSC | $1 \times 10^6$ IV 24 hours post CLP | Lung recovery (human BMSC) | Guldner et al. 2015 [69] |
| Rat, ALI, E. coli induced | Human BMSC | Series 1 $1 \times 10^7$ or $2 \times 10^7$ IV 0.5 hours post E. coli challenge | Survival, IL-10, IL-6, IL-12, TNF-α | Devaney et al. 2015 [43] |
| Mouse, sepsis, CLP | Mouse DMC (auto) | $2 \times 10^6$ IV 4 hours post CLP | Survival, IL-4, IL-5, IFN-γ, IL-1β, IL-6 | Wang et al. 2015 [70] |
| Rat, VILI | Rat BMSC (allo) conditioned medium | $1 \times 10^7$ IV 1.5 – 2.5 hours post VILI initiation | Lung inflammation (IV BMSC only) | Hayes et al. 2015 [71] |
| Mouse, ALI, E. coli induced | Human BMSC | $8 \times 10^5$ IT/IV 4 hours post E. coli challenge | Survival, bacterial clearance, KGF | Monsel et al. 2015 [72] |
| Rat, sepsis-induced organ injury, CLP | Human Wi-MSC + antibiotics | $1 \times 10^6$ IP 6 hours post E. coli challenge | Survival, liver function, kidney function, IL-4, IL-10, NF-κB, IL-1β, IL-6, IFN-γ | Cóndor et al. 2016 [73] |
| Rat, sepsis-induced organ injury, cecal bacteria induced | Rat ADSC (auto) +/− antibiotics | $5 \times 10^5$ IV at 0.5, 6, & 18 hours post-sepsis induction | Survival, kidney function, TNF-α, NF-κB, IL-1β, MMP-9, RANTES | Sung et al. 2016 [74] |

Abbreviations: ADSC, adipose derived mesenchymal stem cell; ALI, acute lung injury; Auto, autologous; Allo, allogeneic; BMSC, bone marrow derived mesenchymal stem cell; CLP, cecal ligation and puncture; CM, conditioned medium; DMC, dermal-derived mesenchymal cells; IP, intraperitoneal; IT, intratracheal; IV, intravenous; LPS, lipopolysaccharide; KGF, keratinocyte growth factor; MenSC, menstrual derived mesenchymal stem cell; RO, retro orbital; UC-MSC, umbilical cord derived mesenchymal stem cell; VILI, ventilation-induced lung injury; WI-MSC, Wharton’s Jelly-derived mesenchymal stem cell; †, an increase relative to baseline value; ‡, a decrease relative to baseline value.

The precise mechanisms by which MSCs may mediate their effects remain for the most part unclear. Several preclinical studies have determined that in sepsis and ALI/ARDS, MSC exposure resulted in a decline in pro-inflammatory cytokines including IL-1α, IL-1β, IL-6, IFN-γ, and TNF-α [46, 49–57, 59, 61, 63–70, 73] and an increase in anti-inflammatory cytokines such as IL-4, IL-5, IL-10 [49–51], [56], [57], [63], [64], [67], [70], [73]. Gupta et al. [49] found that in mice, intrapulmonary administration of BMSC 4 hours after induction of ALI by E. coli endotoxin resulted in improved survival, reduced excess lung water and improved lung histology, resulting in a decrease of bronchoalveolar lavage (BAL) TNF-α and MIP-2 and an
increase of IL-10 levels within BAL and plasma samples. Importantly in the context of ALI/ARDS, BMSC treatment resulted in a decrease in alveolar epithelium permeability. Animals treated with fibroblasts or apoptotic MSCs showed no such shift. It was also determined that MSC engraftment occurred infrequently and that although MSCs do express the LPS receptor complex, its presence did not alter endotoxin distribution. As in vitro transwell-experiments demonstrated that MSC were able to inhibit TNF-α production by alveolar macrophages through a contact-independent mechanism, the authors concluded that the beneficial effects of MSC in this model appeared to be largely mediated by soluble factors. In a CLP model of sepsis, Nemeth et al. [51] reported that an injection of $1 \times 10^8$ BMSC resulted in increased survival, decreased vascular permeability, a reduction of TNF-α and IL-6 and an increase in IL-10. No such effect was seen following injection of fibroblasts, whole bone marrow or heat-killed BMSC. While a beneficial response to MSC could be observed in mice lacking mature T and B cells or NK cells, clodronate depletion of monocytotes and macrophages abolished the MSC effect. Similarly, the MSC effect was abrogated in mice treated with either anti-IL-10 or anti-IL-10 receptor antibodies. The authors demonstrated that LPS treatment of BMSC resulted in an upregulation of PGE₂, which in turn stimulated macrophage production of IL-10. Li et al. [61] showed that after induction of ALI by LPS in rat, human umbilical cord derived MSC (UC-MSC) improved survival, lung histology, wet-dry weight ratio and reduced neutrophil infiltration. However, while UC-MSC led to a reduction in serum concentrations of TNF-α, IL-1β, and IL-6 following LPS challenge, no effect was observed on IL-10 levels. Sepúlveda et al. [46] demonstrated in an LPS sepsis model that treatment with non-senescent human BMSCs resulted in increased survival despite decreasing IL-10 values. Although senescent human BMSCs were able to inhibit lymphocyte proliferation in vitro, the ability to positively influence sepsis was abrogated. In a recent study of CLP induced sepsis, Guldner et al. [69] reported a reduction in TNF-α and in IL-6 that was accompanied by a modest reduction in IL-1β following injection of either $1 \times 10^5$ human BMSCs (hBMSCs) or mouse BMSCs (mBMSCs). An increase in IL-10 was observed in mice treated with hBMSC, whereas mBMSC treatment resulted in a decrease. Both groups displayed similar decreases in lung edema and inflammation; however, hBMSCs were superior in restoring lung function. Interestingly, the authors reported no difference on day 3 survival amongst untreated CLP animals (89%) and those treated with either hBMSC (82%) or mBMSC (96%). The role of MSC in modulating cytokine levels in sepsis syndrome models is undoubtedly complex; concerning IL-10, conflicting results have shown MSCs to both positively [50, 56, 57, 63, 64, 67, 70, 73] as well as negatively [46, 54] influence levels, or alternatively have no effect [59, 60]. There are similar inconsistencies in relation to IFN-γ levels, with groups describing a reduction [50, 57, 73], an increase [70] or no effect [51, 67]. It is likely that this apparent functional heterogeneity is a reflection of differences in experimental models, treatment regimens and MSC sources.

**MSCs Promote Bacterial Clearance**

Seemingly running contrary to their immunosuppressive capacity, treatment with MSCs has been reported to improve bacterial clearance [55, 60]. Although MSC themselves lack phagocytic activity [54], MSCs can stimulate phagocytosis by monocytes [60], macrophages [54] and neutrophils [75]. Gonzalez-Rey et al. [50] reported that in addition to positively influencing the cytokine balance and animal survival, exposure to either human ($1 \times 10^5 - 5 \times 10^8$) or mouse ($1 \times 10^5$) ADSCs resulted in reduced peri-toneal bacterial counts, possibly through modulating activated macrophage activity. MSCs also appear to inhibit bacterial growth through the secretion of antimicrobial compounds including the human cathelicidin antimicrobial peptide LL-37 [76], keratinocyte growth factor (KGF) [77], and lipocalin 2 [59]. Lee et al. [77] examined the effects of hBMSC in an ex vivo perfused human lung model. Application of hBMSC (5 or $10^10$ cells) either one or 2 hours after *E. coli* challenge ($10^9$ or $10^{10}$ CFU) resulted in a significant decrease in bacterial load, improved alveolar fluid clearance and reduced inflammatory cell infiltration. MSCs antimicrobial effect was abolished following inhibition of KGF by neutralizing antibody. In a series of experiments performed by Devaney et al. [43] in a rodent *E. coli* ALI model, it shown that a single dose of between $5 \times 10^5$ and $2 \times 10^9$ of hBMSCs resulted in improved survival, reduced lung injury and a reduced bacterial burden that was also associated with increased IL-37 concentrations. Intravenous and intratracheal administration routes were found to be equally effective in prolonging survival and alleviating ALI symptoms. However, hBMSC applied intravenously led to a reduction in the frequency of alveolar neutrophils while intratracheal hBMSC was more effective at increasing levels of IL-10 and KGF.

**MSCs Enhance Lung Recovery**

Multiple studies examining the effect of MSC in models of lung injury have reported MSC application to be associated with enhanced lung recovery and regain of function. Curley et al. [62] demonstrated in rat that following ventilation-induced lung injury (VILI), intravenous or intratracheal administration of allogeneic BMSC (4 $\times 10^6$ cells) restored lung function, enhanced the alveolar air-space volume and reduced alveolar thickening and decreased markers of inflammation. A similar effect was also reported following intratracheal administration of MSC conditioned media (CM). However, in a follow-up study performed by the same group, intravenously administered CM was found to be largely ineffective at restoring arterial oxygenation, respiratory static compliance, lung wet: dry ratio and reducing inflammation when compared to intravenously administered allogeneic BMSC (1 $\times 10^7$ cells) [71].

**Recent MSC-Derived Therapeutic Strategies**

Cellular-based therapies currently in development for sepsis syndrome and ALI/ARDS treatment have focused on MSC derived from bone marrow or adipose tissue. However, recent studies have also assessed the feasibility of utilizing MSC isolated from alternative sources whilst others are examining the therapeutic efficacy of MSC-derived vesicles. In a recent publication, Cóndor et al. [73] analyzed the efficacy of MSCs derived from human Wharton’s Jelly (WJ-MSCs) in a rat sepsis model. In animals receiving $1 \times 10^6$ WJ-MSC 6 hours after CLP, 5-day survival was significantly increased (87.5% vs. 55.6% in CLP only) and both liver and kidney function were improved. WJ-MSCs treatment resulted in IL-1α, IL-6, and IFN-γ values similar to non-CLP controls. However, there was no detectable effect on either IL-4 or IL-10. In a CLP mouse sepsis model, Alcayaga-Miranda et al. [68] evaluated...
| Study title                                                                 | Indication      | Registry numbers | Study design                          | Estimated enrolment (to received cell therapy) | Cell type       | Dosing schedule                                                                 | Start Date | Est. End Date |
|-----------------------------------------------------------------------------|-----------------|------------------|---------------------------------------|-----------------------------------------------|----------------|--------------------------------------------------------------------------------|------------|---------------|
| A pilot study for the efficacy and safety of mesenchymal stem cell in acute severe respiratory failure (STELLAR-Pilot). | ARDS            | NCT02112500      | Phase II, open label, single group assignment | 10 (10)                                      | Auto BMSC      | Unknown                                                                        | Feb 2014   | Dec 2016      |
| Treatment of severe acute respiratory distress syndrome with allogeneic bone marrow-derived mesenchymal stromal cells (MSC-ARDS). | ARDS            | NCT02215811      | Phase I, open label, single group assignment | 10(10)                                        | Allo BMSC      | Unknown                                                                        | Mar 2014   | Dec 2015      |
| Phase 1 study of recombinant stem cells that repair lung injury in H7N9 infected patients. | ALI/ARDS        | NCT02095444      | Phase I/II, open label, single group assignment | 20(20)                                        | MenSC          | Four infusion; 1 × 10^7 kg/bw IV (twice per week)                              | Mar 2014   | Dec 2016      |
| Prospective, randomized, multicenter phase 2 clinical trial of allogeneic bone marrow-derived human mesenchymal stem cells for the treatment of acute respiratory distress syndrome (START). | ARDS            | NCT02097641      | Phase II, randomized, double blind, single group assignment | 60 (30)                                      | Allo BMSC      | Single infusion; 1 × 10^5 kg/bw IV day one                                      | Mar 2014   | Dec 2017      |
| Cellular immunotherapy for septic shock: A phase I trial (CISS).            | Sepsis          | NCT02421484      | Phase I, open label, single group assignment | 9 (9)                                         | Allogeneic BMSC| Single infusion, IV Cohort 1, 3 × 10^7 kg/bw Cohort 2, 1 × 10^6 kg/bw Cohort 3, 3 × 10^5 kg/bw | May 2015   | Sep 2016      |
|Safety and efficacy of human umbilical-cord-derived mesenchymal stem cell transplantation in acute lung injury (UCMSC-ALI). | ALI             | NCT02444455      | Phase I/II, open label, single group assignment | 20 (20)                                      | Allogeneic UCSC| Three infusions; 5 × 10^7 cells day 1 1.6 × 10^7 cells day 2 1.6 × 10^7 cells day 3 | May 2015   | Dec 2017      |
| A phase Ib/IIa, randomized, double blind, parallel group, placebo controlled, multicenter study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit (SEPCELL). | Sepsis          | 2015-002994-39   | Phase I/II, randomized, double blind, parallel assignment | 180 (90)                                      | Allogeneic ADSC| Two infusions; 1.6 × 10^7 cells day 1 1.6 × 10^7 cells day 2 | Oct 2015   | Jul 2017      |
| A phase 1/2 study to assess the safety and efficacy of multistem therapy in subjects with acute respiratory distress syndrome (MUST-ARDS). | ARDS            | NCT02611609      | Phase I/II, double blind, parallel assignment | 36 (26)                                       | Allogeneic MAPC| Cohort 1, 3 × 10^6 cell Cohort 2, 9 × 10^6 cell Cohort 3, 3 × 10^6 or 9 × 10^5 cell | Jan 2016   | Dec 2017      |
| A phase II trial of mesenchymal stem cells for treatment of acute respiratory distress syndrome in stem cell transplant patients. | ARDS            | NCT02804945      | Phase II, randomized, double blind, parallel assignment | 50 (25)                                       | Allogeneic MSC| Single infusion; 1 × 10^5 kg/bw IV day one                                      | Oct 2016   | Oct 2018      |

Abbreviations: ADSC, adipose derived mesenchymal stem cell; ALI, acute lung injury; Allo, allogeneic; ARDS, acute respiratory disease syndrome; Auto, autologous; BMSC, bone marrow derived mesenchymal stem cell; IV, intravenous; MenSC, menstrual derived mesenchymal stem cell; UCDS, umbilical cord derived mesenchymal stem cell.
human MSCs derived from menstrual fluid (MenSC) in combination with antibiotic therapy. Injection of $7.5 \times 10^5$ MenSC cells promoted survival and bacterial clearance, improved lung histology and was associated with a decrease in markers of multiorgan dysfunction. A synergistic effect was observed when MenSC were combined with Enrofloxacin. At 40 hours, cell-treated animals exhibited reduced TNF-$\alpha$, IL-6, MCP1, and also IL-10. The authors reported that while IL-37 could not be detected, expression of the peptide hormone hepcidin was increased in treated animals, inhibition of which nullified the antimicrobial effect. Wang et al. [70] reported on the ability of murine, nonexpanded, dermal-derived MSCs (DMCs) to attenuate CLP–induced sepsis. Up to $1 \times 7^{13}$ DMCs were recovered from processed dermis samples without the need for further culture. Mice injected with $1 \times 10^6$ DMCs 4 hours after CLP possessed decreased IL-1$\beta$ and IL-6 values and displayed an increase in IL-4, IL-5, and IFN-$\gamma$. However, no significant change in IL-10 level was detected. In addition, DMCs positively influenced macrophage migration and phagocytic activity. At present, preclinical and clinical studies of MSC-based technologies have focused on the use of whole MSCs. However, there is growing body of evidence that extracellular vesicles (EVs), a constituent of MSC CM that includes endosomes and microvesicles, might impart a therapeutic benefit through transporting and delivering MSC-derived protein, microRNA and mitochondria to target cells. The therapeutic capacity of hBMSC-derived MVs was recently compared to that of MSC by Monsel and colleagues [72]. MVs were recovered from a 48-hour culture of $9 \times 10^6$ hBMSC by ultracentrifugation. Similar beneficial effects to E. coli induced ALI were observed in response to MV and MSC intervention. Survival and bacterial clearance was increased in both groups and lung injury was decreased. Preincubation of hBMSC MVs with anti-CD44 antibody impaired the effect on survival, suggesting that cellular uptake of MVs is required in order to elicit a therapeutic effect. Although a detailed assessment of MV-based therapies is beyond the scope of this current review, Monsel et al. [78] has produced a particular thorough examination of the scientific literature in this area.

### MSC in Acute Respiratory Distress and Sepsis Syndromes—The Clinical Experience

Currently, there are only a limited number of reports detailing the response of septic and ALI/ARDS patients to MSC. However, there are a number of ongoing clinical trials registered which are estimated to be completed shortly or within the next 1–2 years (Table 3). One of the earliest studies to examine the safety of MSCs in ARDS patients was conducted by Zheng et al. (NCT01902082) [79]. In this phase I, single-center, double-blind, placebo-controlled study, 12 patients were randomized 1:1 and received a peripheral intravenous infusion of either 100 ml saline or a single dose of allogeneic ADSC equivalent to $1 \times 10^6$ cells/kg bw over 1 hour. The study reported that while ADSC infusion appeared safe, there were no significant differences in total length of hospital stay, ICU-free days, and ventilator-free days or in serum ARDS biomarkers (SP-D, IL-6, IL-8) between treatment arms. However, the authors acknowledged that the study's small sample size and a limited follow-up period of 28 days hampered further analyses. The RUMCESS (NCT01849237) trial, a single-center, open label, randomized study, sought to assess the impact of MSCs in patients with septic shock and severe neutropenia. The primary outcome measure was 28-day mortality; secondary outcome measures included the effect of MSC on organ dysfunction parameters, systemic inflammatory markers and SOFA-score. Of the 27 patients enrolled, 13 received conventional treatment while 14 received conventional treatment plus a single dose of $1 \times 10^6$ MSC IV administered within 10 hours after onset. Galstian et al. [80] reported that the MSC treated group had a significant increase in 28-day survival rates (57% vs. 15%) that was associated with a decrease in SOFA-score. However, there was no difference in post-28 day survival rates. While an improvement in 28-day survival is certainly encouraging, it is difficult to draw further conclusions from this study as no inflammatory marker analysis was performed and there is little information on the type of MSCs used in the study. CELLULA (NCT02328612) was a commercially sponsored, randomized interventional trial designed to study the effects of ADSC in healthy male volunteers treated with LPS. After receiving LPS, 32 volunteers received either IV placebo or $2.5 \times 10^5$, $1 \times 10^6$ or $4 \times 10^6$ cells/kg bw of Cx611, an allogeneic ADSC. Though the trial was registered as complete in April 2015, at the time of writing no peer reviewed results are available. In 2015, Wilson et al. [81] published results of a phase I, multicenter, open label, dose-escalation pilot study, START (NCT01775774). Selecting patients with moderate to severe ARDS, the aim of this study was to assess the safety of allogeneic bone-marrow derived MSCs (BMSC) by measuring the incidence of defined prespecified infusion associated events experienced by three cohorts (9 patients in total) receiving either $1 \times 10^5$, $5 \times 10^6$, and $10 \times 10^6$ cells/kg bw. The study concluded that while all BMSC dose levels were well tolerated, no significant differences in ARDS markers (IL-6, IL-8, ANGPT2, and AGER) between cohorts could be detected. A follow-up phase II efficacy trial is currently ongoing (NCT02097641). Simonson et al. [82] reported on the clinical outcome of two patients diagnosed with severe ARDS treated with $2 \times 10^6$ cells/kg bw allogeneic BMSC. Cell infusion in both patients was uneventful and was completed without complications. At 5 days post-infusion, patient 1 developed nosocomial pneumonia that subsequently responded to antibiotic treatment. Patient 1 was extubated 4 weeks after MSC infusion and patient 2 after 12 days. Both patients showed a decrease in markers of epithelial apoptosis, alveolar-capillary fluid leakage together with a decline in pro-inflammatory cytokines, miRNAs, and chemokines in plasma and BAL fluid. The authors acknowledged that the treatment of these patients generated valuable data, but that larger patient cohorts would be required to thoroughly investigate the response of ARDS patients to MSCs.

### Conclusion

Sepsis syndrome and ALI/ARDS represent a significant treatment challenge and remain a frequent course of death. Despite extensive efforts to develop innovative therapeutic strategies, none so far have translated into a new evidence-based treatment. Compounds which repeatedly showed promise in preclinical and phase I/II trials, have subsequently failed phase III assessment. Most notably human recombinant APC, the only compound to receive marketing authorization for sepsis treatment, was subsequently withdrawn after follow-up phase III studies failed to replicate the patient benefit observed in its initial registration trial [24, 83]. It is hardly surprising then, that research into anti-inflammatory therapeutics for sepsis treatment has been referred to as a “graveyard
for pharmaceutical companies” [84]. Yet studies into MSC-based therapies in sepsis and ALI/ARDS are encouraging and the majority of preclinical results confirm that MSCs are capable of dampening the early pro-inflammatory cascade, decreasing infection and improving survival. Notwithstanding, when interpreting these results, particular attention should be paid to the animal model used. Is the model sufficient and capable of accurately reflecting the clinical complexities of the disease course? Certainly, a criticism that can be leveled at the majority of preclinical research involving these syndromes is a heavy reliance on results obtained from small inbred animal models which are radically dissimilar to the diverse septic patient demographic. Large animal models including baboon, pig, and sheep have been developed for the study of ALI/ARDS and these may more accurately represent various clinical facets of the human disease course. Indeed, encouraging results have been reported in porcine [85] and ovine [86] ALI/ARDS models regarding the effects of MSC treatment. However as preclinical research programs utilizing large animal models might take longer to complete, be more costly and require further specialized handling requirements, there usage is somewhat limited. Animal models utilize an artificially induced sepsis that, in order to aid further experimental analysis, is typically accelerated, clearly defined, and reproducible. Finally, in models designed to assess the impact of MSCs, cell therapy is typically applied before or at the time of sepsis induction; a treatment regimen which is clearly unrealistic for the majority of septic patients. The results from early clinical trials have provided tantalizing hints that MSCs can provide a therapeutic benefit. However, further interpretation of the effect of MSC in sepsis syndrome is hindered due to small sample sizes, difference in experimental design and biomarker selection. We contend that future trials consider including standardized immunological analysis of treated patients to simplify inter-study comparisons and promote pooling of data. For example, DuraClone IM panels [87] are increasingly being used within studies of cellular therapy in solid organ transplantation [47, 88]. The next generation of MSC sepsis studies will need to take into account the innate heterogeneity of sepsis syndrome and clearly patient selection and stratification will be of paramount importance. To address this issue within our own planned phase I/II study of third-party MSC-based product in sepsis syndrome, we will select only those patients presenting with sepsis of an abdominal origin that occurs following surgical interventional and/or source control. While there is currently insufficient clinical evidence concerning the efficacy of MSC in the treatment of sepsis syndrome and ARDS, results from recently completed clinical trials are expected shortly and may clarify what the future holds for MSC-based therapeutics.

**AUTHOR CONTRIBUTIONS**

C.L.J., Y.S., and M.H.D.: manuscript writing, final approval of manuscript.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors indicate no potential conflicts of interest.

---

**REFERENCES**

1. Adhikari NK, Fowler RA, Bhagwanjee S et al. Critical care and the global burden of critical illness in adults. Lancet 2010;376:1339–1346.

2. Fleischmann C, Scherer A, Adhikari NK et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193:259–272.

3. Pittet D, Rangel-Frausto S, Li N et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: Incidence, mortalities and outcomes in surgical ICU patients. Intensive Care Med 1995;21:302–309.

4. Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 2007;33:606–618.

5. Salvo I, de Cian W, Musico M et al. The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995;21(suppl 2):S244–S249.

6. Tuchpichon K, Koyfman A, Foran M. Sepsis, severe sepsis, and septic shock: A review of the literature. Afr J Emerg Med 2015;5:127–135.

7. Deutschman CS, Tracey KJ. Sepsis: Current dogma and new perspectives. Immunity 2014;40:463–475.

8. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.

9. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801–810.

10. Lyle NH, Pena OM, Boyd JH et al. Barriers to the effective treatment of sepsis: Anti-microbial agents, sepsis definitions, and host-directed therapies. Ann N Y Acad Sci 2014;1323:101–114.

11. Levy MM, Fink MP, Marshall JC et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:1760–1774.

12. Simpson SQ. New sepsis criteria: A change we should not make. Chest 2016;149:1117–1118.

13. Deutschman CS. Imprecise medicine: The limitations of sepsis-3. Crit Care Med 2016;44:857–858.

14. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform regulating activation of inflammatory caspases and processing of pro-β-lactamase. Mol Cell 2002;10:417–426.

15. Huang W, Tang Y, Li L. HMGB1 is a potent proinflammatory cytokine in sepsis. Cytokine 2010;51:119–126.

16. Boomer JS, To K, Chang KC et al. HMGB1, a potent neuroinflammatory mediator, is upregulated in septic mice. J Immunol 2001;167:2549–2560.

17. Monneret G, Venet F, Pachot A et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306:2594–2605.

18. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139–162.

19. Lagu T, Rothberg MB, Shieh MS et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012;40:754–761.

20. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2016. Crit Care Med 2016;44:390–486.

21. Opal SM, Fischer CJ Jr., Dhainaut JF et al. Confirmation of interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 2000;28:119–126.

22. Abraham E, Latifre PF, Garbino J et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29:503–510.

23. Abraham E, Latifre PF, Garbino J et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29:503–510.

24. Bernard GR, Vincent JL, Latifre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.

25. Werdan K, Pilz G, Bujdosso O et al. Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med 2007;35:2693–2701.
et al. Mesenchymal stem cells are short-lived cells upon mesenchymal stem cell-lymphocyte growth factor beta 1 play non-redundant roles.

van der Poll T. Preclinical sepsis models. Surg Infect (Larchmt) 2012;13:287–292.

Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006;34:344–353.

Fink MP. Animal models of sepsis. Virulence 2014;5:143–153.

Wang P, Chaudry IH. A single hit model of polymicrobial sepsis: Cecal ligation and puncture. Sepsis 1998;2:227–233.

Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739–2749.

Le Blanc K, Tammik M, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogen responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11–20.

Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141–150.

English K, Ryan JM, Tobin L et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009;156:149–160.

Prevoost T, Zancolli M, Canevali P et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007;92:881–888.

Obermayer N, Popp FC, Soeder Y et al. Conversion of Th17 into IL-17A(neg) regulatory T cells: A novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J Immunol 2014;193:4988–4999.

Polak JM, Bishop AE. Stem cells and tissue engineering: Past, present, and future. Ann N Y Acad Sci 2006;1068:352–366.

Barry FP, Murphy JM, English K et al. Immunogenicity of adult mesenchymal stem cells: Lessons from the fetal allograft. Stem Cells Dev 2005;14:252–265.

Casiraghi F, Remuzzi G, Abbate M et al. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev 2013;9:65–79.

Eggenhofer E, Benseler V, Kroemer A et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012;3:297.

Devaney J, Horie S, Masterson C et al. Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 2015;70:E62–E65.

Marquez-Curits LA, Janowska-Wieczorek A, McGann LE et al. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. Cytopharmacology 2012;1:167–179.

Pollock K, Sumstad D, Kadidlo D et al. Clinical mesenchymal stem cell products undergo functional changes in response to freezing. Cytotherapy 2015;17:38–45.

Sepeulveda JC, Tome M, Fernandez ME et al. Cell senescence abrogates the therapeutic potential of human mesenchymal stromal cells in the lethal endotoxemia model. Stem Cells 2014;32:1865–1877.

Soeder Y, Loss M, Johnson CL et al. First-in-human case study: Multipotent adult progenitor cells for immunomodulation after liver transplantation. STEM CELLS TRANSPL. 2015;4:899–904.

Paones J, Garcia-Olmo D, Vanasse G et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. Lancet 2016;388:1281–1290.

Gupta N, Su X, Popov B et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179:1855–1863.

Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929–939.

Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42–49.

Bi LK, Tang B, Zhu B et al. Systemic delivery of il-10 by bone marrow-derived stromal cells has therapeutic benefits in sepsis. Prog Biochem Biophys 2010;37:678–685.

Lee SH, Jang AS, Kim YE et al. Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in liver fibrosis. Respir 2010;8:11:16.

Mei SH, Haisma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047–1057.

Kim ES, Chang YS, Choi SJ et al. Intratraheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Inflamm Res 2012;61:12:108.

Liang ZX, Sun JP, Wang P et al. Bone marrow-derived mesenchymal stem cells protect rats from endotoxin-induced acute lung injury. Chin Med J (Engl) 2011;124:2715–2722.

Sun J, Han ZB, Liao W et al. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4+CD25+ Forkhead Boxp3 (FOXP3)+ regulatory T cells and balancing anti- and pro-inflammatory factors. Cell Physiol Biochem 2011;27:587–596.

Chang CL, Lee S, Sung HC et al. Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med 2012;10:244.

Gupta N, Krasnodembskaya A, Kapetanaki M et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67:533–539.

Krasnodembskaya A, Samaranj G, Song Y et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012;302:L1100–1103.

Li J, Li D, Liu X et al. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond) 2012;9:33.

Curley GF, Ansari B, Hayes M et al. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology 2013;118:924–932.

Yang H, Wen Y, Hou-you Y et al. Combined treatment with bone marrow mesenchymal stem cells and methylprednisolone in paraparot-induced acute lung injury. BMC Emerg Med 2013;13(suppl 1):55.

Zhao Y, Yang C, Wang H et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells on pulmonary impact injury complicated with endotoxemia in rats. Int Immunopharmacol 2013;15:246–253.

Chen HH, Lin KC, Wallace CG et al. Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cells against sepsis-induced kidney injury. J Pineal Res 2014;57:16–32.

Chao YH, Wu HP, Wu KH et al. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis. PLoS One 2014;9:e110338.

Pedrazza L, Lunardelli A, Luft C et al. Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. Inflamm Res 2014;63:719–728.

Alcayaga-Miranda F, Cuenca J, Martin A et al. Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res Ther 2015;6:199.

Geldner A, Maron-Gutierrez T, Abreu SC et al. Expanded endothelial progenitor cells mitigate lung injury in septic mice. Stem Cell Res Ther 2015;6:230.

Wang Y, Tan L, Jin J et al. Non-cultured dermal-derived mesenchymal cells attenuate sepsis induced by cecal ligation and puncture in mice. Sci Rep 2015;5:16973.

Hayes M, Curley GF, Masterson C et al. Mesenchymal stem cells are more effective than the MSC secretome in diminishing injuries and enhancing recovery following ventilator-induced lung injury. Intensive Care Med Exp 2015;3:29.
72 Monsel A, Zhu YG, Gennai S et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med 2015;192:324–336.

73 Condor JM, Rodrigues CE, Sousa Moreira R et al. Treatment with human Wharton’s jelly-derived mesenchymal stem cells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction. STEM CELLS TRANSNL MED 2016;5:1048–1057.

74 Sung PH, Chiang HJ, Chen CH et al. Combined therapy with adipose-derived mesenchymal stem cells and ciprofloxacin against acute urogenital organ damage in rat sepsis syndrome induced by intrapelvic injection of cecal bacteria. STEM CELLS TRANSNL MED 2016;5:782–792.

75 Hall SR, Tsoyi K, Ith B et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: The importance of neutrophils. STEM CELLS 2013;31:397–407.

76 Krasnodembskaya A, Song Y, Fang X et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. STEM CELLS 2010;28:2229–2238.

77 Lee JW, Krasnodembskaya A, McKenna DH et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013;187:751–760.

78 Monsel A, Zhu YG, Gudapati V et al. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther 2016;16:859–871.

79 Zheng G, Huang L, Tong H et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study. Respir Res 2014;15:39.

80 Galstian GM, Parovichiokova EN, Makarova PM et al. The results of the Russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial). Blood 2015;126:2220.

81 Wilson JG, Liu KD, Zhuo H et al. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 2015;3:24–32.

82 Simonson OE, Mougiakakos D, Heldring N et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. STEM CELLS TRANSNL MED 2015;4:1199–1213.

83 Ranieri VM, Thompson BT, Barie PS et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055–2064.

84 Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003;112:460–467.

85 Moodley Y, Sturm M, Shaw K et al. Human mesenchymal stem cells attenuate early damage in a ventilated pig model of acute lung injury. Stem Cell Res 2016;17:25–31.

86 Asmussen S, Ito H, Traber DL et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014;69:819–825.

87 Streitz M, Miloud T, Kapinsky M et al. Standardization of whole blood immune phenotype monitoring for clinical trials: Panels and methods from the ONE study. Transplant Res 2013;2:17.

88 Geissler EK. The ONE Study compares cell therapy products in organ transplantation: Introduction to a review series on suppressive monocyte-derived cells. Transplant Res 2012;1:11.

89 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874.